Research programme: fullerene based antioxidant therapeutics - Tego BioSciences/Merck

Drug Profile

Research programme: fullerene based antioxidant therapeutics - Tego BioSciences/Merck

Alternative Names: C3

Latest Information Update: 24 Mar 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tego BioSciences
  • Class Fullerenes; Small molecules
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Neurological disorders

Most Recent Events

  • 11 Jul 2007 Fullerene based antioxidant therapeutics are available for partnering (
  • 25 Jun 2007 C Sixty Acquisition Corp is now called Tego BioSciences Corporation
  • 26 Mar 2007 C Sixty Inc has been acquired by Arrowhead Research Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top